Consistently with this conclusion, alternative treatment strategies targeting IFN-I in the most advanced phase of development including baricitinib (JAKi, active phase 3) and BIIB059 (anti-BDCA2 mAB, ongoing phase 3) have shown efficacy on skin manifestations of SLE (Wallace et al., 2018; Furie et al., 2019a). This evidence concerns the gene CLEC4C and systemic lupus erythematosus.